The prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy was similar to that in the geriatric population without cancer. It was also consistent with previous studies on elderly cancer population. Pain was found to be a factor related to depressive symptoms. The prevalence of depression may be reduced by pain control. The treatment of depression may both improve the patient's quality of life and enhance their compliance with treatment.
Background Increased risk of cardiovascular morbidity and mortality has been reported in psoriatic arthritis (PsA), a member of a spondyloarthropathy. Fetuin-A is a novel biomarker related with vascular calcification and atherosclerosis. In recent years there is a considerable interest regarding fetuin-A and atherosclerosis. In this respect it has been studied in some rheumatic disease including rheumatoid arthritis. However, available data regarding the association of fetuin-A and inflammatory rheumatic diseases is still limited. Objectives In this study we aimed to investigate the association between fetuin-A, disease activity and PsA. Methods 97 non-diabetic PsA patients who fulfilled the CASPAR criteria and 57 age and sex matched healthy controls were included in the study. Disease activity was assessed by using Composite Psoriatic Disease Activity Index (CPDAI). Patients were also evaluated with BASFI, BASDAI, DAS28-CRP, HAQ. PASI scores were calculated. Serum lipids, hsCRP, ESR, and fetuin-A were studied. Results There were 97 PsA patients (48 [25-65] years, 32M/65F) and 57 healthy subjects (43 [31-57] years, 24M/33F). Disease duration of the PsA patients was 4 (0-43) years. Age, sex distributions, anthropometric measures such as body mass index were similar between the groups. Biochemical parameters such as fasting glucose, lipids (triglyceride, total, LDL and HDL), creatinine clearance were not different PsA patients and controls. On the other hand hs-CRP and ESR were significantly higher in the patients' group. Fetuin-A concentrations were significantly lower in the patients than in controls (Table 1, P<0.001). When the PsA group was divided into peripheric (n=14), axial (n=52) and both peripheric and axial subtypes (n=31) fetuin A remained significantly lower in the each PsA group compared to controls (peripheric: 1122 [571-1493], axial 1172 [456-2017] and both peripheric and axial subtypes 1113 [486-1580] vs. controls 1442 [63-1896]; P<0.05). On the other hand, there were no differences between the PsA groups regarding fetuin A. There were significant correlations (P<0.05) between fetuin-A concentrations and CPDAI, PASI, hs-CRP and ESR (-0.26, -0.25, -0.3, and -0.26 respectively). However, fetuin-A did not show correlations with BASFI, BASDAI, HAQ and DAS28-CRP. Table 1. Clinical and laboratory characteristics of the study group Psoriatic arthritis, n=97 Healthy controls, n=57 P value Age (years) 48 (25–65) 43 (31–57) 0.09 Sex, M/F (%) 32/65 (33/67) 24/33 (42.1/57.9) 0.29 Waist circumference (cm) 97 (65–129) 94 (67–125) 0.08 BMI (kg/m2) 26.9 (18.9–41) 26.4 (17.9–38.4) 0.17 Smoking, % 28.9 40.4 0.15 Glucose (mg/dL) 89 (63–121) 92 (63–112) 0.86 HDL cholesterol (mg/dL) 46 (26–93) 47 (31–92) 0.72 LDL cholesterol (mg/dL) 126 (75–290) 123 (73–233) 0.48 Total cholesterol (mg/dL) 200 (134–398) 198 (141–349) 0.94 Triglyceride (mg/dL) 106 (37–362) 117 (55–245) 0.58 Creatinine clearance (mL/min) 120.8 (70–197) 121.4 (79–187) 0.59 Fetuin-A (μg/mL) 1143 (456–2017) 1442 (63–189...
Background Several studies have found a higher prevalence of type 2 diabetes mellitus in patients with psoriasis and psoriatic arthritis (PsA). Interestingly, a complete remission of psoriasis has been observed following immediately after the gastric bypass surgery in obese diabetic patients before any weight loss could have occurred, most likely due to the increased levels of GLP-1. There have been also diabetic cases who have showed improvements in psoriasis under the treatment with GLP-1 receptor agonists and with dipeptidyl peptidase-IV (DPP-IV) inhibitors.GLP-1 was suggested to have anti-inflammatory effects in addition to its effects on glucose homeostasis. Objectives To investigate the GLP-1 level and its relationship with inflammation in patients with psoriasis and PsA. Methods This study included non-diabetic PsA patients and healthy controls. Disease activity was assessed in the patients by using “Composite Psoriatic Disease Activity Index (CPDAI)” which assessed five domains of disease: peripheral arthritis, dactylitis, enthesitis, axial involvement and skin findings. High-sensitive C-reactive protein (hs-CRP) levels were also investigated for the assessment of the disease activity. Fasting blood GLP-1 levels were measured in PsA patients by using ELISA method and compared with those measured in the controls. Results There were 97 PsA patients who fulfilled the CASPAR criteria. Fifty-seven healthy sex, age- and –body mass index (BMI) matched hospital workers were evaluated as controls (Table 1).14 patients had predominantly axial and 52 had predominantly peripheral disease. 22 (17.5%) were receiving corticosteroids. 12 patients (7.8%) were on anti-TNF treatment, 78 (%80.4) were on methotrexate.There was no statistically significant difference in the GLP-1 levels between PsA patients and healthy controls. GLP-1 levels in patients with active disease were also not different from inactive patients and controls. No difference was determined in GLP-1 levels between patients with predominantly axial and predominantly peripheral disease and healthy controls. GLP-1 levels in patients with psoriasis and PsA were not correlated with the other disease activity scores including BASDAI, DAS28, PASI and hsCRP levels. There was also no correlation between GLP-1 level and functional disease index (BASFI) and also health assessment parameters (HAQ, ASQoL). The subgroup analysis in patients who were not taking glucocorticoid treatment (n:27) revealed the similar results. Table 1.Demographic, clinical and laboratory features of the patients and controls Psoriatic arthritis, n=97 Healthy controls, n=57 P value Median age (yrs) 48 (25–65) 43 (31–57) 0.09 Sex, M/F 32/65 24/33 0.29 Median disease duration (yrs) 4 (0–43) Smoking status, % 28.9 40.4 0.15 GLP-1 (pmol/L) 15.2 (3.6–58.6) 15.3 (3–56.3) 0.77 Insulin (μIU/ml) 7.4 (2–24.7) 5.7 (2.5–14.2) 0.02 HOMA-IR 1.6 (0.4–5.6) 1.3 (0.4–3.3) 0.054 ESR (mm/h) 26 (2–100) 12 (3–35) <0.001 hs-CRP (mg/L) 4.9 (0.7–65.2) 1.5 (0.2–6.8) <0.001 *GLP-1: gluc...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.